CDK4 and melanoma: A DMS analysis performed in the melanoma Meljuso cell line with the ATP-competitive CDK4/6 inhibitor palbociclib uncovered hotspot residues in CDK4 and CDK6 involved in resistance, which were also confirmed in ERK2 [75].